English

On February 3, 2023, Structure Therapeutics, an incubated company of Tee Labs—a biopharmaceutical professional incubator located in Zhangjiang, Pudong, Shanghai—was listed on the Nasdaq Stock Market in the United States. Structure Therapeutics is a clinical-stage global biopharmaceutical company dedicated to developing novel oral therapeutics for a variety of chronic diseases. The company utilizes world-class proprietary…

On November 29, Full-Life Technologies (“Full-Life”), a Tee Labs Incubatee, announced the acquisition of Focus-X Therapeutics (“Focus-X”), a New Jersey, USA-based company developing targeted radiopharmaceuticals for the treatment of cancer based on its proprietary peptide engineering technology. The acquisition, valued at $245 million, is expected to close in the first quarter of 2023. Founded in…

The co-founder of Full-Life Technologies told R&D-based Medicine, “The range of targets that can be developed for RDCs (Radiopharmaceutical-Drug Conjugates) is not very limited. In theory, RDCs can pursue any target that ADCs can, and they also have the advantage of a ‘theranostic’ approach.” Driven by the dual forces of pharmaceutical giants and capital, Radiopharmaceutical-Drug…

  Following a review by the Shanghai Pudong New Area Science, Technology and Economic Commission, Tee Labs was officially recognized as an Innovative Incubator of Pudong New Area on August 11, 2022. Tee Labs and its incubated companies are now eligible to enjoy corresponding incentive policies. Since its official launch in September 2021, Tee Labs…

ShouTi Inc. Announces Company Name Change to Structure Therapeutics ShouTi Inc. announced today that it has secured $33 million in an oversubscribed financing, building on its $100 million Series B financing completed in October 2021. In addition, the company has completed dosing in its Phase 1 single ascending dose (SAD) study of GSBR-1290 for the…

In mid-June 2022, China successfully conducted a long-term animal study of a percutaneous ventricular assist device (pVAD). The animal study, which involved the pVAD running continuously for 10 days (with a designed duration of 5 days), has now been successfully completed. This achievement validates the long-term operational safety, reliability, and effectiveness of this pVAD product…

Shanghai, China & Brussels, Belgium – May 26, 2022 – Full-Life Technologies (“Full-Life”) today announced it completed a $37 million (USD) Series A financing round to advance the development of its radiopharmaceutical oncology product pipeline and its radiotechnology production platform. The financing round was led by Sequoia China, together with Yunion Healthcare Ventures, Junson Capital, CD…

December 21, 2021, Belgium and Shanghai, China: Full-Life Technologies (“Full-Life) today announced a $10 million seed round financing to advance the development of its broad pipeline of Precision Nuclear Medicines as well as its Nuclear Technology platform to address supply chain challenges in Nuclear Medicine. Chengwei Capital was the sole & lead investor and Full-Life was…

On December 4th, BayHelix held its second offline event of the year at the Tee Labs incubator in Zhangjiang, Shanghai. Themed “Bidding Farewell to the Old Year, Nurturing Body and Mind,” the event specially invited Leon Chen, a national-level referee and national bodybuilder, and Mark Tang, Managing Director of New York Health Capital, both of…

Tee Labs Incubatee: ShouTi Successfully Raises $100 Million in Series B Financing，Leveraging Advanced Computational and Structure-Based Drug Design Platform to Accelerate the Development of Life-Changing Medicines for Patients ShouTi Inc., a clinical-stage biopharmaceutical company, is dedicated to developing life-changing medicines for patients by leveraging advanced computational and structure-based technologies. The company announced on October 20th…